Blood
Articles in this Issue
Lymphoid malignancy and clonality in the POT1-mediated long telomere syndrome
Abstract Long telomere length (TL) extends replicative capacity in vitro and predisposes to clonal hematopoiesis. We characterized the cancer phenotype in 51 individuals from 24 fa...
Ruxolitinib for ciltacabtagene autoleucel–associated refractory diarrhea
Abstract Intractable diarrhea is a recently described complication following B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T-cell therapy for multiple m...
A stem and progenitor cell–derived gene expression signature is prognostic for survival in myelofibrosis
Abstract In this study, we hypothesized that transcriptomic features among disease-driving hematopoietic stem and progenitor cells (HSPC) could improve current paradigms for risk s...
Tfr2 is necessary for acute iron-dependent hepcidin induction in mice with Tfr1-deficient hepatocytes
Abstract In hepatocytes, transferrin receptor 1 (Tfr1) plays a limited role in iron acquisition but negatively regulates signaling to the iron hormone hepcidin (Hamp) through its i...
Myeloid/lymphoid neoplasms with <i>FGFR1</i> rearrangement and pemigatinib
Abstract Myeloid/lymphoid neoplasms with FGFR1 rearrangement (M/LN-FGFR1) are rare, heterogenous diseases due to fusion transcripts originated by translocations of FGFR1 with diffe...
Focusing a sPOTlight on <i>POT1</i>
A tale of two transferrin receptors
NXTAGE: a phase 1/2 study of NXT007 to assess safety, pharmacokinetics, and efficacy in hemophilia A without inhibitors
Abstract NXT007 is a next-generation, activated factor VIII (FVIIIa)–mimetic bispecific antibody under investigation in the phase 1/2 NXTAGE trial. Here, we report the primary anal...
Is gene therapy a cure for β-thalassemia?
Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma
Abstract In this retrospective analysis of 584 patients who received chimeric antigen receptor T-cell therapy for large B-cell lymphoma at 6 Australian centers, no association was...
MRD-2 in the GHSG HD21 trial assessed by a validated circulating tumor DNA sequencing assay
Abstract Beyond cure, major goals in patients with Hodgkin lymphoma (HL) are tailoring treatment to a patient’s individual risk for relapse to reduce acute and late toxicities, ide...
Making the case for ruxolitinib in CAR T-cell enterocolitis
Dual-antigen–targeting T-cell immunotherapies in MM: circumventing tumor heterogeneity and preventing antigen escape
Abstract B-cell maturation antigen (BCMA)– or G protein–coupled receptor class C group 5 member D (GPRC5D)–directed T-cell immunotherapies have substantially improved the survival...
MRD testing in Hodgkin lymphoma: filling the knowledge gaps
Classic Hodgkin lymphoma with <i>IGH</i> :: <i>CCND1</i> rearrangement: evidence of clonal relation to preceding mantle cell lymphoma
Generational advancement of factor VIIIa mimetics
Adding transcriptomic features to MF prognostic models
Long-term efficacy and safety results of betibeglogene autotemcel gene therapy for transfusion-dependent β-thalassemia
Abstract Betibeglogene autotemcel (beti-cel) gene therapy for transfusion-dependent β-thalassemia (TDT) involves autologous transplantation of hematopoietic stem and progenitor cel...